UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial
Dr. Jeanne Marrazzo speaks during a press conference September 3, 2020.
The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.
During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.
“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”
Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.
But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.
“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”
Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.
“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”
She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.
“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”
Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Auburn fires coach Hugh Freeze following 12th loss in his last 15 SEC games
The 56-year-old Freeze failed to fix Auburn’s offensive issues in three years on the Plains, scoring 24 or fewer points in 17 of his 22 league games. He also ended up on the wrong end of too many close matchups, including twice this season thanks partly to questionable calls.
In a ‘disheartening’ era, the nation’s former top mining regulator speaks out
Joe Pizarchik, who led the federal Office of Surface Mining Reclamation and Enforcement from 2009 to 2017, says Alabama’s move in the wake of a fatal 2024 home explosion increases risks to residents living atop “gassy” coal mines.
‘It’s like feeling the arms of your creator just wrapped around you’: a visit to a special healing Shabbat
Members of Temple Emanu-El in Birmingham gathered recently for their traditional Friday Shabbat service. But this particular service was different, as could be seen by all the people dressed in their finest pink.
Space Command is coming to Huntsville. What might that mean for first-time homebuyers
While Huntsville has been a more affordable market than other growing cities, what’s it been like for those looking for their first home?
Colorado says relocation of Space Command to Alabama is ‘punishment’ for mail-in voting
The litigation announced by Colorado Attorney General Phil Weiser asks a federal judge to block the move as unconstitutional.
Breaking down Alabama’s CHOOSE Act
It’s been a year since Alabama legislators passed the CHOOSE Act allowing families to apply for state funds to use towards homeschool expenses and tuition for participating private schools. The Alabama Daily News’ education reporter Trisha Powell Crain has been diving into how the funds are being used. WBHM’s Andrew Gelderman sat down with her to talk about what we’re seeing so far.
